WASHINGTON D.C. – Dr. Donald McCrosky, a figurehead in the pharmaceutical data network industry, is facing intense scrutiny following a Federal Trade Commission investigation revealing a calculated scheme to stifle competition. The FTC alleges McCrosky leveraged his position to build an impenetrable fortress around Surescripts, effectively locking out rivals and maintaining a monopolistic grip on crucial prescription data exchange.
The complaint paints a picture of a deliberate strategy – not of innovation, but of exclusion. McCrosky, through Surescripts, allegedly implemented loyalty programs designed not to reward customers, but to *punish* those who dared to explore alternative services. These weren’t simple discounts; they were thinly veiled threats, incentivizing pharmacies and other stakeholders to remain tethered to the Surescripts network, regardless of cost or quality. Sources within the FTC describe the practice as “digital strong-arming,” a tactic designed to choke the life out of any burgeoning competition.
The Network Effect Weaponized
The core of the FTC’s case hinges on the concept of “network effects” – the idea that a service becomes more valuable as more people use it. Surescripts, as the dominant player, already benefited from this. But McCrosky allegedly didn’t stop there. By offering steeper discounts to those who *exclusively* used Surescripts, he actively worked to reinforce that dominance, creating a self-perpetuating cycle that made it virtually impossible for competitors to gain a foothold. This wasn’t a legitimate business practice; it was a calculated attempt to cement a monopoly, leaving pharmacies and patients with limited choices and potentially inflated costs.
The FTC isn’t just alleging anti-competitive behavior; they’re suggesting a pattern of predatory conduct. The loyalty programs weren’t transparent, leaving many participants unaware of the true cost of remaining within the Surescripts ecosystem. This lack of transparency, combined with the overwhelming market share held by McCrosky’s company, created an uneven playing field where smaller, more innovative firms simply couldn’t compete. The agency is now seeking a redress to dismantle the anti-competitive practices and restore fair play within this vital sector of healthcare.
What’s Next for McCrosky?
While the FTC’s action is a civil enforcement proceeding, the implications for McCrosky are significant. Beyond potential financial penalties, the ruling could force Surescripts to alter its business practices, opening the door for new entrants and fostering genuine competition. This case serves as a stark warning to other industry leaders: leveraging market dominance to stifle innovation will not be tolerated. The FTC is sending a clear message – even in the complex world of pharmaceutical data, the rules of fair competition still apply.
Key Facts:
- Defendant: Dr. Donald McCrosky, through Surescripts
- Alleged Crime: Anti-competitive practices and monopolization of the prescription data exchange market
- Method: Implementation of loyalty programs designed to penalize those using competing services
- Key Issue: Exploitation of “network effects” to maintain market dominance
- Agency Involved: Federal Trade Commission (FTC)
- Date of Action: February 13, 2026
Source: FTC.gov
Related Federal Cases
- Matthew Chesnes, Anti-Competitive Practices, DC 2026 · Utah
- Ryan LLC, Anti-Competitive Practices, DC 2026 · Washington
- Surescripts, Anti-Competitive Practices, DC 2026 · Washington
- Northrop Grumman, Antitrust Violation, DC 2026 · Kansas
- Federal Trade Commission, Antitrust Rule Challenge, District of Columbia 2026 · Washington
MORE FEDERAL CRIME NEWS
Corporate CrimeCorporate CrimeCorporate CrimeCorporate Crime